What Our Analysts Know About BridgeBio Pharma

By Blake Campbell • Monday, October 13 10:17 • Permanent Link

Large-cap Health Care company BridgeBio Pharma has moved 0.9% so far today on a volume of 298,456, compared to its average of 2,465,317. In contrast, the S&P 500 index moved 1.0%.

BridgeBio Pharma trades -15.54% away from its average analyst target price of $66.32 per share. The 19 analysts following the stock have set target prices ranging from $41.0 to $95.0, and on average have given BridgeBio Pharma a rating of buy.

Anyone interested in buying BBIO should be aware of the facts below:

BridgeBio Pharma has moved 115.2% over the last year, and the S&P 500 logged a change of 11.8%
Based on its trailing earnings per share of -4.13, BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -13.6 while the S&P 500 average is 29.3
BBIO has a forward P/E ratio of -18.3 based on its forward 12 month price to earnings (EPS) of $-3.06 per share
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Based in Palo Alto, the company has 725 full time employees and a market cap of $10.71 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.